Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
As of my last knowledge update in September 2021, the U.S. Food and Drug Administration (FDA) had already approved the first “artificial pancreas” system for type 1 diabetes in 2016. The system, known as the Medtronic MiniMed 670G, is a hybrid closed-loop insulin delivery system.
The Medtronic MiniMed 670G system consists of an insulin pump and a continuous glucose monitor (CGM) that work together to automatically adjust insulin delivery based on real-time glucose levels. The CGM measures glucose levels in the interstitial fluid, and the insulin pump adjusts insulin delivery accordingly, helping to keep blood sugar levels within a target range.
The system uses a closed-loop algorithm that can temporarily suspend insulin delivery when blood sugar levels are predicted to drop too low (hypoglycemia) and can also automatically increase insulin delivery when blood sugar levels are rising. However, it is essential to note that the system is not fully autonomous and still requires user interaction, such as inputting mealtime carbohydrates and calibrating the CGM periodically.
Since the approval of the MiniMed 670G, there may have been additional advancements and approvals in the field of artificial pancreas systems for type 1 diabetes. Newer systems may have additional features and improved algorithms to further enhance glucose control and simplify the user experience.
It’s essential for individuals with type 1 diabetes to work closely with their healthcare providers to determine the most appropriate diabetes management plan, including the use of technology such as artificial pancreas systems. While these systems can offer significant benefits in glucose control, they are not suitable for everyone, and treatment decisions should be made based on individual health needs and considerations.
For the latest information on artificial pancreas systems and diabetes management technologies, it is recommended to refer to updates from the FDA, medical device manufacturers, and reputable diabetes organizations.